EMCrit FOAM Feed

EMCrit FOAM Feed

By Scott D. Weingart, MD FCCMScienceMedicineHealth & Fitness
Download on the App Store
  • Favorites

    1,064

    Followers

  • Latest release

    7 days ago

  • Typical duration

    29 min

    per episode

  • If it hooks

    52%

    finish an episode

Based on Podcast App listening data

All EMCrit FOAM Feed episodes

  • EMCrit 071 – Critical Questions on Massive Transfusion Protocols with Kenji Inaba
    Today, I got to interview Kenji Inaba; an incredibly prolific trauma surgeon from USC/LA County, California. He is the SICU director and surgical critical care fellowship director. If you flip through any issue of the Journal of Trauma, odds are good that Kenji will have an article there.
    Here are the questions I got to ask:
    From the military studies, 1:1 (PRBCs to FFP) has emerged as the goal during hemostatic resuscitation. The civilian data is less robust, but there are cohort studies out there. Some of them suffer from survival bias and confounding by indication, but enough is out there for most of US trauma centers to attempt to meet the 1:1 goal? What are you folks doing at USC?

    This excellent editorial (Resuscitation 82 (2011) 627–628) discusses the problems with 1:1 civilian studies and why we should shoot for this ratio anyway.

    What is your transfusion goal with your 1:1. We are giving a mix of PRBC and FFP whenever the patient’s MAP drops below 65 and we don't even bothering looking at the labs to determine which of these two products the patient needs. We are using them just like some saline in the dehydrated patient. If their MAP drops below our goal, they get the PRBC and FFP 1:1 until we get the MAP back up. How about you folks?

    For more on this see Rich Dutton's Interview

    Where do platelets fit into the mix? At many hospitals they are not available in large amounts and most places are using old platelets and non-type-specific platelets. Some of your own work is on this very subject, should we be matching 1:1 with platelets as well? How about if we only have old, non-type-specific products?

    See Kenji's Paper on the topic of old platelets.

    Now most of our European and Canadian Colleagues have moved to concentrates instead of FFP and platelets. They use PCCs and fibrinogen concentrates in the initial stages of the hemostatic resuscitation. Is this the future?

     

    Are you using TEG or ROTEM, if so how does this fit into the picture? Should it be available in the ED, the OR?

     

    Let’s talk TXA. I interviewed Tim Coats, one of the lead authors of Crash 2, last week—he advocates using it with any trauma patient who will need any amount of PRBCs, and to give it as early as possible. I think I agree with him. When are you USC guys giving TXA?

     

    MATTERs trial shows that intermittent boluses may be effective rather than starting the infusion. We are giving the 10-minute bolus in the trauma room and then deferring infusion to the STICU if the patient still has active bleeding. Starting an infusion in the trauma bay can be frustrating when we are trying to pour blood products in. How about you?

     

    Are you using Rh specific in males? If you give O+ to an Rh - male are you giving rhogam?

    This is the AAST Plenary Paper (J Trauma 2012;72(1):48) we mentioned

    I am a member of the Kenji fan club; I think you folks will be as well after hearing his sincerity and brilliance.
    22 min
  • Episode 2 – ACEP 2011 Clinical Policy on Pulmonary Embolism (PE)
    Welcome to the second episode of Practical Evidence, a podcast about the evidence you NEED to know but may not have time to read.

    This month we discuss the American College of Emergency Physicians’ Pulmonary Embolism Clinical Policy(2011)
    What’s EMCrit Drinking?
    This month, I’m drinking a Dreamweaver by Troeg Brewery
    Please visit our bandwidth sponsor:
    Please check out our bandwidth sponsor EB Medicine for great offers exclusively for our listeners.
    10 min
  • EMCrit Wee – Abandon Epinephrine?
    Two studies were mentioned:
    Hagihara A, et al. Prehospital Epinephrine Use and Survival Among Patients With Out-of-Hospital Cardiac Arrest. JAMA. 2012;307(11):1161-1168
    See Ryan's blog for some great commentary.

    &
    The PACA Trial: Jacobs et al. Effect of adrenaline on survival in out-of-hospital cardiac arrest: A randomised double-blind placebo-controlled trial. Resuscitation. 2011 Sep;82(9):1138-43.
     
    6 min
  • Podcast 70 – Airway Management with Rich Levitan
    The best lecture on Airway Management--Ever?
    Rich Levitan is one of the best teachers on the skills of laryngoscopy--or as he would probably put it, epiglottoscopy. Here is an hour long lecture he delivered last month at Mount Sinai School of Medicine. It is surely one of the best airway lectures I have ever heard.

    Want to hear more from Dr. Levitan? Visit his airway site at airwaycam.com.

    or, read his incredible book:


    Get a big discount on the Emergency Medicine Critical Care Journal


    Just go to ebmedicine.net/emcrit
    Want the handout?
    Here are Rich Levitan's Slides
    Audio-Only Version
    Right-Click on this Link and Choose Save-as
    This episode is eligible for CME
    Now, on to the Vodcast...
    1 hr 16 min
  • EMCrit Wee – On Editing Comments and Ad Hominem Attacks
    I am not arrogant enough to believe that I can understand any man's or woman's motivations, so I only argue their words & actions, but I don't force this viewpoint upon any of you. I do ask that you name yourself on any comments, accurately and in a verifiable manner. If you do that I will publish anything you write only editing out curse words for the delicate eyes of my listeners.

    This wee was prompted by comments on episode 69.

    This post is closed for comments, please go to the link above to make comments regarding this post.
    6 min
  • EMCrit Podcast 69 – The Future of CPR with Keith Lurie and Demetris Yannopoulos
    The Future of CPR
    I got to interview two cutting edge researchers on what CPR will look like in the next decade; their answers were fascinating.
    Flow-Enhanced CPR
    They discuss the use of the impedance threshold device and the active-compression/decompression device to augment flow during CPR. See the results of the ResQ trial listed below to see what this does in cardiac arrest patients.

    Note: Dr. Lurie is the founder, chief medical officer, and a major shareholder of the company that manufactures these two devices. Dr. Yannopoulos has no conflicts of interest.

    Reperfusion Injury Protection
    Stutter CPR is giving 3 cycles of 20 seconds of compressions/ventilations, 20 seconds of pause. In pigs, this has markedly reduced the reperfusion injury when resuscitating a patient with prolonged arrest.
    New Medications
    Sodium nitroprusside (in addition to small doses of epi and flow-enhanced CPR) increases flow to the heart and the brain. May also blunt reperfusion injury to heart and brain. In addition adenosine and cyclosporine A may have a role as well.
    Note: None of this is ready for clinical use--this may be the future, it is not the present
    Want More?

    * A presentation on the topic by Dr. Yannopoulos
    * Read the ResQ Trial (Lancet  2011;377(9762):301–311)

    Supplemental Audio
    More on the ROC-Primed Trial and the ResQ Trial (MP3 File--Right Click and choose Save As)

    More on Dosing and Intra-Arrest Hypothermia and Cath (MP3 File--Right Click and choose Save As)
    Update

    * Recent 15-minute pig cardiac arrest study provides continued evidence of ischemic post-conditioning (Resuscitation  Volume 84, Issue 8, August 2013, Pages 1143–1149)
    * Review article on the physiology of CPR

    This podcast is eligible for EMCrit CME
    And Now to the Podcast...
     
    26 min
  • Episode 1 – Penetrating Neck Trauma Guidelines
    Welcome to the first episode of Practical Evidence, a podcast about the evidence you NEED to know but may not have time to read.

    This month we discuss the Eastern Association for the Surgery of Trauma’s (EAST) guidelines on the management of penetrating trauma.
    What’s EMCrit Drinking?
    This month, I’m drinking a Mary’s Maple Porter from Brooklyn Brewery
    Please visit our bandwidth sponsor:
    Please check out our bandwidth sponsor EB Medicine for great offers exclusively for our listeners.
    10 min
  • Podcast 67 – Tranexamic Acid (TXA), Crash 2, & Pragmatism with Tim Coats
    Crash 2 and Tranexamic Acid
    One of the most exciting and underutilized therapies for trauma is tranexamic acid (txa). TXA inhibits the breakdown of clot--it is an anti-fibrinolytic. Is there evidence for using this in trauma patients?

    First came the Crash 2 Trial (Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010; 376: 23–32),

    then the subgroup reanalysis (Lancet. 2011 Mar 26;377(9771):1096) showing the benefit of treatment as early as possible.

    Recently, the MATTERS trial (Arch Surg. 2012; 147:113-119) was published demonstrating the benefits of TXA in military situations, particularly massive transfusion.

    How about an incredible review from the J Trauma (2011; 71(1) Supplement S9)

    Then there is this paper describing current military protocol rationale.

    To discuss TXA in Trauma, I got to interview Dr. Tim Coats, one of the primary authors of Crash 2.
    Here is a List of Resources from the Crash 2 Investigators
    This is the official resource page from Crash 2

     

    We also discussed the concept of the pragmatic trial...
    Future Research in Emergency Medicine: Explanation or Pragmatism
    (Emerg Med J 2011;28(12):1004)



    Listen to the podcast excerpt on pragmatic trials (mp3--right click the link and choose save-as if you want to download)

    In an amazing demonstration of synchronicity, Jeff Guy of the ICU Rounds Podcast put out a tranexamic acid episode on the same day.

    Minh Le Cong provided this prehospital protocol for TXA use.

    An incredible review article can be found at this citation (Journal of TRAUMA 2011;71(1) July Supplement)
    Update...
    This article published in J Trauma (74(6), May 2013, p 1587–1598) gives an excellent summary of the current evidence as of 5/2013


    Summary: What Do We Know?

    * TXA is associated with a 1.5% reduction in 28-day all-cause mortality in adult trauma patients with signs of bleeding (SBP < 90 mm Hg, heart rate > 110 beats per minute, or both, within 8 hours of injury) in a large pragmatic prospective randomized placebo-controlled trial.
    * What is critical is the modest effect on the overall population: All-cause mortality was “significantly” reduced from 16.0% to 14·5% (NNT, 67). The risk of death caused by bleeding overall was “significantly” reduced from 5.7% to 4·9% (NNT, 121).
    * TXA signal for benefit was in the most severe shock group (admission SBP <= 75 mm Hg), 28-day all-cause mortality of 30.6% for the TXA group versus 35.1% for the placebo group (RR, 0.87; 99% CI 0.76–0.99).
    * 1,063 deaths (35%) were caused by bleeding in the CRASH-2 Trial.
    * TXA had greatest impact on reduction of death caused by bleeding in the severe shock group (SBP <= 75 mm Hg) (14.9% vs. 18.
    22 min